CD19 and neoplasm: CAR19-NK-92 cells were co-cultured under three conditions: in the absence of dasatinib (DMSO control), in the presence of dasatinib (25 nM), or following a 24-hour dasatinib treatment, the inhibitor was removed by washing before co-culturing with CD19-positive tumor cell lines.